Transforming Hemophilia A Treatment with Bispecific Antibodies – NEJM Group
NEJM Group shared a post on LinkedIn about a recent article by Flora Peyvandi, published in The New England Journal of Medicine, adding;
“Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa, who developed a prophylactic therapy for hemophilia A, have received the 2026 Lasker-DeBakey Clinical Medical Research Award.
For decades, the treatment of hemophilia A rested on a single principle: replacing factor VIII, the missing clotting factor.
Plasma-derived and recombinant factor VIII concentrates transformed a once-fatal disease into a manageable chronic condition through prophylaxis and treatment.
But factor VIII has a relatively short half-life and thus is administered through frequent intravenous infusions, and neutralizing anti-factor VIII antibodies (inhibitors) that render replacement therapy ineffective develop in up to one third of patients with severe hemophilia A.
By showing that the coagulation cascade could be activated in the absence of factor VIII, Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa (of Chugai Pharmaceutical) overcame these limitations.
They developed a bispecific antibody that mimics blood coagulation factor VIlI, an achievement recognized by the 2026 Lasker-DeBakey Clinical Medical Research Award.”
Title: Reengineering Coagulation with a Bispecific Antibody
Authors: Flora Peyvandi
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 14, 2026, 06:51Alexander Hof: Species-Specific Roles of MPO Deficiency
-
Sep 14, 2026, 06:36Patrick Badertscher: PVI With vs Without Posterior Wall Isolation in Persistent AF
-
Sep 14, 2026, 06:31Mona Ranade: Can Mechanical Thrombectomy Play a Role in Septic Thrombophlebitis?
-
Sep 14, 2026, 06:30Alexsander Santiago: Tranexamic Acid – Why Timing Matters in Critical Bleeding
-
Sep 14, 2026, 06:25Gevorg Yaghjyan: How Surgical Intelligence Is Transforming Operating Rooms
-
Sep 14, 2026, 04:43Christina (Tina) P.: Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis
-
Sep 14, 2026, 04:38Aravind Palraj: Uncovering the Drivers of Occlusive Retinal Vasculitis in Young Patients
-
Sep 14, 2026, 04:33Mostafa Elshazly: ERS Has just Relesed 2026 Update on the Treatment of PAH
-
Sep 14, 2026, 04:24Sourabh Dwivedi: Important Hemoglobinopathies – High-Yield-Alert!